Alliance Global Partners raised the firm’s price target on NeuroOne Medical to $3.33 from $2.20 and keeps a Buy rating on the shares. Citing Q4 results and the company’s launch timeline for OneRF, the firm is adjusting its FY24 model, introducing FY25 estimates and rolling its valuation multiple onto its 2025 estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMTC:
- NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
- Options Volatility and Implied Earnings Moves Today, December 14, 2023
- Is NMTC a Buy, Before Earnings?
- NeuroOne Medical receives FDA 510(k) clearance to market OneRF system
- Options Volatility and Implied Earnings Moves This Week, December 11 – December 15, 2023
